Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325694 | 0.85 | MAPT (0.36) | ALDH1A1GAALMNATSHRNPC1 | |
| SCHEMBL18317372 | 0.81 | LMNA (0.64) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL23793284 | 0.74 | EPHX2 (0.40) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL18325698 | 0.71 | ALDH1A1 (0.44) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL24909975 | 0.70 | LMNA (0.60) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL30066529 | 0.69 | HTT (0.35) | ALDH1A1GAATSHRNPC1HPGD | |
| SCHEMBL18317199 | 0.68 | LMNA (0.49) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL31648531 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL18325699 | 0.65 | ALDH1A1 (0.40) | ALDH1A1GAALMNATSHRNPSR1 | |
| SCHEMBL13463822 | 0.65 | LMNA (0.47) | GAALMNATSHRNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | ALDH1A1 429/4885GAA 24/4885LMNA 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.